Loading
Epigenetic clocks and senescence markers run fast after cancer treatment, and nobody has shown that moving one matters. The way to find out is to make the clock a secondary endpoint in a trial whose primary endpoint is physical function.
The measurement side of biological ageing in survivors is in reasonable shape. The intervention side is empty, and the market filling it is not. The design problem is that a trial with a clock as its primary endpoint proves nothing a person would notice, while a trial with a clinical endpoint is expensive, so neither gets run and the question stays open.
The resolution is to stop choosing. Any adequately powered randomised trial of an intervention in survivors should bank samples and prespecify a biological-age secondary analysis: does the marker move, and does movement in the marker track movement in the function endpoint within the same people? Answer that a few times and the field learns whether these markers are worth using as endpoints at all, which is the question that currently blocks every geroprotective trial in oncology.
PROFFi is the first trial with this shape in cancer survivors: fisetin with and without tailored exercise, four arms, with change in six-minute walk distance as the primary endpoint. The cheapest version of this idea is a funder requirement rather than a new trial, attached to the survivorship trials already being paid for.
Shares Nobody has tested whether reversing measured biological ageing changes anything, Epigenetic age after cancer treatment, What actually works after treatment, Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it and the tags rejuvenation, survivorship, biological-ageing.
Shares PROFFi: fisetin and exercise to prevent frailty in breast cancer survivors, Nobody has tested whether reversing measured biological ageing changes anything, Senescent cells and p16 after chemotherapy, Epigenetic age after cancer treatment and the tags rejuvenation, survivorship, biological-ageing.
Shares Epigenetic age after cancer treatment, What actually works after treatment, Biomarkers are not validated or standardised and the tags rejuvenation, survivorship, biological-ageing.
Shares Nobody has tested whether reversing measured biological ageing changes anything, What actually works after treatment and the tags rejuvenation, survivorship.
Shares Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it, Biomarkers are not validated or standardised and the tags rejuvenation, survivorship, open-problem.
Shares Nobody has tested whether reversing measured biological ageing changes anything, What actually works after treatment and the tags rejuvenation, survivorship.
Shares Nobody has tested whether reversing measured biological ageing changes anything, What actually works after treatment and the tags rejuvenation, survivorship.
Shares Epigenetic age after cancer treatment, What actually works after treatment and the tags rejuvenation, survivorship, biological-ageing.